Margin resik: Personalis, Inc. (PSNL)

Personalis Inc (PSNL) - logo korporat

Personalis, Inc. is recognized as a benchmark in precision oncology due to its high-precision genomic diagnostics. Sales margins reflect profit dynamics, with the value maintained at -147.70. The company ensures stable demand through genetic tests for clinics and pharma behemoths, while its narrow specialization in sequencing is offset by the implementation of an innovative liquid biopsy IT platform.

Rentabilitas dodolan resik Personalis Genomics (PSNL): kanggo periode 04.07.2022 - 19.11.2026

Rincian metrik keuangan lan pasar Personalis Corp (PSNL)

- nilai pasar lan prakiraan target analis:
- indikator kapitalisasi bursa perusahaan:
Analisis kabeh metrik perusahaan:Personalis, Inc.
Produk asil prodhuksi Personalis Inc

The scaling of genomic tumor profiling and the expansion of diagnostic tests through pharma partnerships directly impact the monetization efficiency of Personalis, Inc. (PSNL). By analyzing the underlying net sales margin, an investor assesses the ratio of bottom-line profit to revenue, which determines management's ability to transform commercial growth into actual income and control operational risks through the dynamics of this indicator.

Pesaing Personalis, Inc. (PSNL)

ONC: Margin dodolan resik|Margin resik Halozyme Inc. (HALO)|Margin resik RevMed|Rentabilitas dodolan resik AAPG (Ascentage Pharma Group)|Margin dodolan resik CGON|UroGen Pharma - Rentabilitas dodolan resik|Bicara Therapeutics - Rentabilitas dodolan miturut bathi resik|Tingkat bathi resik ERAS|DCTH: Rentabilitas dodolan miturut bathi resik|YmAbs - Rentabilitas resik perusahaan|aurabiosciences.com (AURA) - Margin resik|Candel Therapeutics Inc. - Tingkat bathi resik|Margin resik Accuray Inc.|Margin resik SELLAS Life Sciences Group SLS|Margin dodolan resik ACTU|CTOR - Margin resik|Margin dodolan resik HURA (TuHURA Biosciences, Inc.)|Tingkat bathi resik TARA|FATE: Rentabilitas dodolan miturut bathi resik|WHWK (aadibio.com) - Rentabilitas dodolan resik|TCRX (TScan Therapeutics, Inc.) - Rentabilitas dodolan miturut bathi resik|Margin resik Champions Oncology Corp (CSBR)|XBIT (XBiotech Inc.) - Margin dodolan resik|CVM (CEL-SCI Corporation) - Rentabilitas resik perusahaan|Margin dodolan resik OSTX|Margin dodolan resik Radiopharm Theranostics Ltd (RADX)|Margin dodolan resik ARTV (Artiva Biotherapeutics)|Margin dodolan resik Adlai Nortye Ltd. ANL|Veru Inc - Margin dodolan resik|Margin dodolan perusahaan Tempest Therapeutics TPST|XLO: Margin dodolan resik|Enochian BioSciences (RENB) - Margin dodolan resik|Rentabilitas dodolan miturut bathi resik MURA|Kairos Pharma Ltd - Margin bathi resik|Margin dodolan resik OKUR|CytoMed Therapeutics Limited (GDTC) - Tingkat bathi miturut bathi resik|Margin dodolan resik CRIS (Curis, Inc.)|APLM: Rentabilitas dodolan resik|Tharimmune Corporation - Margin dodolan resik|ADVB: Margin resik|GNPX: Margin dodolan resik|CLDI (Calidi Biotherapeutics Inc.) - Margin resik|Margin resik Sunshine Biopharma, Inc.|Margin dodolan resik xeneticbio.com|Margin resik Salarius (SLRX)|Rentabilitas dodolan miturut bathi resik Purple Biotech PPBT|Margin resik American Oncology Network, Inc. AONC|BeiGene, Ltd. (BGNE) - Margin resik|Checkpoint Therapeutics Inc. - Margin dodolan resik|Tingkat bathi resik ELEV (Elevation Oncology)|ICAD (iCAD Corp) - Rentabilitas dodolan miturut bathi resik|Ikena Oncology, Inc. - Tingkat bathi resik|Rentabilitas dodolan miturut bathi resik NTBL|VIRX: Tingkat bathi resik|Margin resik MorphoSys Corporation (MOR)|NAYA - Margin resik|Margin dodolan resik AAPGV (Ascentage)